Dermatology specialist Galderma (SWX:GALD) on Thursday announced the publication of positive Phase III OLYMPIA 1 trial results for nemolizumab in JAMA Dermatology.
The drug demonstrated significant improvements in itch and skin lesions in patients with moderate-to-severe prurigo nodularis.
Nemolizumab, a first-in-class monoclonal antibody targeting IL-31, showed rapid and sustained relief from itch and sleep disturbance. The drug has already been approved by the US Food and Drug Administration (FDA) for the treatment of prurigo nodularis in adults and is currently under review by regulatory authorities worldwide for both prurigo nodularis and atopic dermatitis.
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Merck reports positive Phase 3 data for investigational two-drug HIV regimen doravirine/islatravir
60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study
Minovia Therapeutics' MNV-201 receives FDA Orphan Drug Designation for Myelodysplastic Syndrome
BeOne Medicines' sonrotoclax receives FDA Breakthrough Therapy Designation for MCL
Ascletis selects once-monthly SQ GLP-1R/GIPR dual peptide agonist, ASC35, for clinical development
Celltrion's biosimilar EYDENZELT (aflibercept-boav) approved by US FDA
Rigel Pharmaceuticals begins dose expansion phase of R289 study in lower-risk MDS
Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio